Dr. Levy on Repeat Testing in NSCLC

Video

In Partnership With:

Benjamin P. Levy, MD, discusses the importance of repeat testing in non–small cell lung cancer.

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the importance of repeat testing in non—small cell lung cancer (NSCLC).

Repeat testing at diagnosis is important for patients whose initial tissue or liquid biopsy was inconclusive, says Levy. An inconclusive liquid biopsy may indicate a patient is not shedding circulating tumor DNA, says Levy. In these cases, repeat testing may reveal a genetic mutation.

Patients who develop resistance to a therapy should also be considered for repeat testing, says Levy.

Additionally, patients who progress on genotype-directed therapies like osimertinib (Tagrisso) or alectinib (Alecensa) should be considered for repeat testing as it can help optimize subsequent therapy for these patients, concludes Levy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,